Y- Shaped Pegylated Interferon (YPEG-IFNα-2a) Plus Ribavirin in Egyptian Patients With Untreated Chronic Hepatitis C
Phase 2
- Conditions
- Self EfficacyHepatitis C
- Interventions
- Drug: pegylated interferon alpha 2a YPEG-IFN α-2a 180mcg
- First Posted Date
- 2011-04-04
- Last Posted Date
- 2011-04-04
- Lead Sponsor
- BioGeneric Pharma
- Target Recruit Count
- 300
- Registration Number
- NCT01327729
- Locations
- 🇪🇬
Kasr Alaini school of medicne, Cairo, Egypt
© Copyright 2025. All Rights Reserved by MedPath